Ezose Sciences and Hirosaki University to Collaborate in Glycomics Research
News May 02, 2012
Ezose Sciences Inc. and Hirosaki University have announced that they have formed a collaboration in glycomics research to identify new biomarkers for use in predicting and monitoring the progression of prostate cancer and other urological cancers.
The research will examine serum and urine samples collected by Hirosaki clinical investigators from well-characterized patient and control populations in Japan.
Ezose will conduct the glycan analysis at its US laboratories using its proprietary GlycanMap® technology platform.
“This agreement marks another step that scientists at Ezose and in universities are taking together to improve our understanding of the role of glycans in health and disease,” said Hidehisa Asada, Ph.D., Vice President, Research & Development at Ezose.
Asada continued, “Given the already established clinical utility of glycan-based biomarkers in certain cancers, we believe that further studies in oncology hold promise for identifying other novel biomarkers that could help guide clinical practice.”
Chikara Ohyama, M.D., Ph.D., Professor and Chairman, Department of Urology at the Hirosaki University Graduate School of Medicine, said: “Glycomics is beginning to come into its own as a basic tool in biomedical research. We look forward to applying this new technology to unmet medical needs in managing urologic cancers through the complementary contributions of Ezose’s scientists and our own.”
Under terms of the agreement, Ezose is granted exclusive rights by Hirosaki University to develop and commercialize new biomarkers resulting from the collaboration.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE